^
Association details:
| Biomarker: | CD47-MET fusion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Durable response to crizotinib in an advanced lung adenocarcinoma patient harboring rare CD47-MET fusion: a case report
Excerpt:
He was diagnosed with stage IV lung adenocarcinoma harboring a CD47 (EX7)-MET (EX15) fusion, detected by next-generation sequencing (NGS)….The patient achieved partial response (PR) to first-line treatment of crizotinib with a progression-free survival (PFS) of 8 months.
DOI:
10.21037/tcr-22-141
